Related Experiment Video
Updated: Jul 10, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
[Experimental study of 99mTc-antisense DNA for tumor imaging]
Chengzhong Fan1, D J Hnatowich
1Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China. Chengzhong.fan@yahoo.com
Summary
This study explored radiolabeled antisense oligonucleotide DNA for tumor imaging in mice. Antisense DNA showed feasible tumor targeting in vivo, particularly in KB-G2 tumors, suggesting potential for future diagnostic applications.
Area of Science:
- Molecular Biology
- Nuclear Medicine
- Oncology
Background:
- Antisense oligonucleotides (ASOs) offer targeted therapeutic potential.
- In vivo imaging of ASOs is crucial for assessing delivery and efficacy.
- Radiolabeling ASOs enables quantitative biodistribution and tumor targeting assessment.
Purpose of the Study:
- To evaluate the feasibility of using radiolabeled antisense DNA for in vivo tumor imaging.
- To compare the tumor targeting efficiency of antisense DNA versus sense DNA in different tumor models.
- To determine the biodistribution and hybridization activity of radiolabeled oligonucleotides.
Main Methods:
- Two human tumor xenografts (KB-G2, KB-31) in nude mice were used.
- Intratumoral administration of radiolabeled (99mTc-MAG3) antisense and sense DNA oligonucleotides.
- Whole-body imaging, tissue biodistribution analysis (%ID/g), and gel electrophoresis for hybridization activity.
Main Results:
- Radiolabeled antisense and sense DNA oligonucleotides exhibited similar hybridization activities.
- Whole-body imaging revealed enhanced targeting of antisense DNA in KB-G2 tumors but not KB-31 tumors.
- Significantly higher tumor accumulation (%ID/g) of antisense DNA was observed in KB-G2 (14.7% vs 8.5%) compared to sense DNA, with no significant difference in KB-31 tumors.
Conclusions:
- In vivo tumor targeting using radiolabeled antisense DNA is feasible.
- Statistically significant tumor accumulation of antisense DNA was demonstrated in the KB-G2 model.
- Further optimization of tumor delivery and normal tissue clearance is necessary for clinical translation of antisense imaging.
